• Our products

  • 1

Oncology

ABSTRAL® is the novel, rapidly-disintegrating, sublingual formulation of fentanyl, a well-established opioid used for the management of episodes of breakthrough pain experienced by cancer patients who are already receiving opioid analgesics for chronic pain.

HALAVEN® (eribulin mesylate) Injection is a chemotherapy that offers an opportunity to live longer for women whose metastatic breast cancer (mBC) has progressed after at least 2 types of mBC therapy. Previous therapy should have included an anthracycline and a taxane for either early or advanced breast cancer. Halaven is developed from a natural substance found in a sea sponge, and is the only medicine discovered in its class of chemotherapy.

LENVIMA® is indicated for the treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine (RAI).

PECFENT® is a nasally administrated spray which contains PecSys®. PecFent® is designed to optimise the absorption of fentanyl, matching drug absorption and clinical effect to the profile of a break through cancer pain episode experienced by cancer patients who are already receiving opioid analgesics for chronic pain.

SANCUSO® (Granisetron Transdermal System) is indicated for the prevention of nausea and vomiting in chemotherapy induced nausea and vomiting (CINV) in patients receiving moderately and/or highly emetogenic chemotherapy regimens of up to 5 consecutive days duration.  It is the first and only treatment for nausea and vomiting that does not require pills or an injection. It is a transdermal patch placed on the outside part of the upper arm that provides continuous control of nausea and vomiting through transdermal delivery.

ONCOTYPE DX® personalizes treatment options and improves outcomes. The Oncotype DX breast cancer test examines the activity of 21 genes in a patient’s breast tumor tissue to provide personalized information for tailoring treatment based on the biology of their individual disease. The test is supported by multiple rigorous clinical validation studies confirming the test’s ability to predict the likelihood of chemotherapy benefit as well as the chance of cancer recurrence in early-stage breast cancer. The test is intended for use in all newly diagnosed patients with early-stage (stage I, II or IIIa), breast cancer who have node-negative or node-positive (1-3), estrogen receptor-positive (ER+), HER2-negative disease. Oncotype DX testing helps patients and their physicians to optimize their cancer care and outcomes, enabling many patients to avoid unnecessary procedures and therapies.

Guardant Health AMEA is a joint venture between SoftBank and Guardant Health, a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. The Guardant Health oncology platform is designed to leverage its capabilities in technology, clinical development, regulatory and reimbursement to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs. In pursuit of its goal to manage cancer across all stages of the disease, Guardant Health has launched multiple liquid biopsy-based tests, Guardant360 and GuardantOMNI, for advanced stage cancer patients, which fuel its LUNAR development programs for recurrence and early detection. Since its launch in 2014, Guardant360 has been used by more than 7,000 oncologists, over 60 biopharmaceutical companies and all 28 National Comprehensive Cancer Network Centers in the United States. Visit our website: https://www.guardanthealthamea.com.

*for full prescribing information please refer to your locally approved label*

Products

  • 1